

The Board:

1. Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Tables 1a and 1b of Section IV to GF/B35/ER16 (“Tables 1a and 1b”);
2. Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Tables 1a and 1b, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;
3. Acknowledges the grant duration and related funding originally approved by the Board for those country components that participated in the concept note process in 2013 as part of the transition to the allocation-based funding model authorized under GF/B28/DP05 (the “Early Applicants”) will end on or before 31 December 2016 and accordingly will need additional funding to bridge the relevant program implementation until 31 December 2017, the typical end date of grant programs arising from the 2014 - 2016 allocation period;
4. Approves the additional incremental funding and implementation period recommended for the EHRN regional grant, being an Early Applicant grant, as listed in Table 2 of Section IV to GF/B35/ER16 based on the available funding that the Finance and Operational Performance Committee (the “FOPC”) validated pursuant to GF/FOPC17/DP02;
5. Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and
6. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.

01 Table 1a: Secretariat's Funding Recommendation on Additional Funding from the 2014 Allocation (Country Applicants)

| N | Applicant | Disease component | Proposed Principal Recipient (Grant Name) | Grant End Date | Currency | Total Program Budget | Sources | | Recommended Total Incremental Funding | Incentive Funding included in Total Incremental Funding | Unfunded Quality Demand | Domestic Commitment |
|---|-----------------------------------|-------------------|---|----------------|----------|----------------------|------------------|---------------------------------|---------------------------------------|---|-------------------------|---------------------|
| | | | | | | | Existing Funding | Recommended Incremental Funding | | | | |
| 1 | Albania | TB/HIV | ALB-C-MOH | 31-Dec-19 | US\$ | 5,823,184 | 15,891 | 5,807,293 | 5,807,293 | n/a | 0 | 10.4 million |
| 2 | El Salvador | Malaria | SLV-M-MOH | 31-Dec-19 | US\$ | 2,000,000 | 0 | 2,000,000 | 2,000,000 | n/a | 11,631,327 | 10,166,758 |
| 3 | Guatemala ¹ | Malaria | GUA-M-MSPAS | 30-Jun-18 | US\$ | 6,914,168 | 6,914,168 | 0 | 0 | n/a | 0 | 4,396,408 |
| 4 | Guinea | TB | GIN-T-PLAN | 31-Dec-17 | US\$ | 3,894,373 | 1,061,241 | 2,833,132 | 2,833,132 | n/a | 0 | 1.32 million |
| 5 | Middle East Response ² | Integrated | QSF-Z-IOM | 31-Dec-18 | US\$ | 43,825,967 | 20,151,152 | 23,674,815 | 23,674,815 | n/a | 0 | n/a |

¹ The Guatemala malaria grant is a simplified application with no material reprogramming.

² The Middle East Response includes funding through the allocations for Palestine HIV, Palestine TB, Syria HIV, Syria TB, Yemen HIV, Yemen malaria and Yemen TB.

Table 1b: Secretariat's Funding Recommendation on Additional Funding from the 2014 Allocation (Regional Applicants)

| N | Applicant | Disease component | Currency | Grant name | Grant end date | Total Program Budget | Sources | | Recommended Total Incremental Funding | Incentive Funding included in Total Incremental Funding | Unfunded Quality Demand | Domestic commitment |
|---|---|-------------------|----------|---------------|----------------|----------------------|------------------|---------------------------------------|---------------------------------------|---|-------------------------|---------------------|
| | | | | | | | Existing funding | Incremental amount for Board approval | | | | |
| 1 | Alliance Nationale Contre le SIDA (ANCS) | TB/HIV | US\$ | QPF-C-ANCS | 31-Dec-19 | 5,892,274 | 0 | 5,892,274 | 5,892,274 | n/a | 0 | n/a |
| 2 | Eurasian Coalition on Male Health (ECOM) | HIV/AIDS | € | QMZ-H-ECOM | 31-Dec-19 | 2,998,706 | 0 | 2,998,706 | 2,998,706 | n/a | 882,580 | n/a |
| 3 | Handicap International | HIV/AIDS | € | QPF-H-HandINT | 31-Dec-19 | 2,905,284 | 0 | 2,905,284 | 2,905,284 | n/a | 268,000 | n/a |
| 4 | India HIV/AIDS Alliance | HIV/AIDS | US\$ | QSA-H-IHAA | 31-Dec-19 | 5,000,000 | 0 | 5,000,000 | 5,000,000 | n/a | 0 | n/a |
| 5 | Organismo Andino de Salud – Convenio Hipólito Unanue (ORAS-CONHU) | TB | US\$ | QRA-T-ORAS | 31-Dec-19 | 6,110,000 | 0 | 6,110,000 | 6,110,000 | n/a | 0 | n/a |
| 6 | South Asia RCM | HIV/AIDS | US\$ | QSD-H-SCF | 31-Dec-17 | 6,600,000 | 2,386,638 | 4,213,362 | 4,213,362 | n/a | n/a | n/a |

Table 2: Secretariat's Recommendation on Early Applicants

| N | Applicant | Disease Component | Grant Name | Currency | Period of Extension (Months) | Previously Approved Grant Budget | Revised Budget for Board Approval | Original Existing Funding | Additional Existing Funding | Incremental Funding Already Approved | Additional Incremental Funding for Board Approval | Total Additional Incremental Funding for Board Approval | Revised Unfunded Quality Demand |
|---|--|-------------------|------------|----------|------------------------------|----------------------------------|-----------------------------------|---------------------------|-----------------------------|--------------------------------------|---|---|---------------------------------|
| 1 | Eurasian Harm Reduction Network (EHRN) | HIV/AIDS | QMT-H-EHRN | € | 9 | 4,561,958 | 5,574,936 | 0 | 0 | 4,561,958 | 1,012,978 | 1,012,978 | 5,474,352 |